151. Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T
- Author
-
Stirrat, Colin t., Alam, Shirjel R., MacGillivray, Thomas J., Gray, Calum D., Forsythe, Rachael, Dweck, Marc R., Payne, John R., Prasad, Sanjay K., Petrie, Mark C., Gardner, Roy S., Mirsadraee, Saeed, Henriksen, Peter A., Newby, David E., and Semple, Scott I.K.
- Subjects
Medicine(all) ,Inflammation ,Science & Technology ,Cardiac & Cardiovascular Systems ,Radiology, Nuclear Medicine & Medical Imaging ,CONTRAST AGENT ,DIAGNOSIS ,USPIO ,1102 Cardiovascular Medicine And Haematology ,CLINICAL-TRIAL ,SUPERPARAMAGNETIC IRON-OXIDE ,Nuclear Medicine & Medical Imaging ,THALASSEMIA ,ULTRASMALL ,REPRODUCIBILITY ,Cardiovascular System & Cardiology ,PARTICLES ,MACROPHAGES ,Life Sciences & Biomedicine ,Cardiac ,MRI - Abstract
BACKGROUND: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) can detect tissue-resident macrophage activity and identify cellular inflammation. Clinical studies using this technique are now emerging. We aimed to report a range of normal R2* values at 1.5 and 3 T in the myocardium and other tissues following ferumoxytol administration, outline the methodology used and suggest solutions to commonly encountered analysis problems.METHODS: Twenty volunteers were recruited: 10 imaged each at 1.5 T and 3 T. T2* and late gadolinium enhanced (LGE) MRI was conducted at baseline with further T2* imaging conducted approximately 24 h after USPIO infusion (ferumoxytol, 4 mg/kg). Regions of interest were selected in the myocardium and compared to other tissues.RESULTS: Following administration, USPIO was detected by changes in R2* from baseline (1/T2*) at 24 h in myocardium, skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and myocardium, kidney, liver, spleen, blood and bone at 3 T (p CONCLUSION: Ferumoxytol-enhanced MRI is feasible at both 1.5 T and 3 T. Careful data selection and dose administration, along with refinements to echo-time acquisition, post-processing and analysis techniques are essential to ensure reliable and robust quantification of tissue enhancement.TRIAL REGISTRATION: ClinicalTrials.gov Identifier - NCT02319278 . Registered 03.12.2014.
- Published
- 2016